Extended Delivery Pharmaceuticals, LLC (EDP) is a development
stage biotechnology company developing a long acting form of
Insulin.
More than 285 million people worldwide have diabetes. The
World Health Organization (WHO) projects that deaths from
diabetes will double by 2030. WHO estimates that direct
expenditures for diabetes therapy to exceed 418 billion
“International Dollars” in 2010.
Insulin is used in the treatment of diabetes for millions of
people. Currently used forms of insulin however force patients
to perform daily, sometimes multiple daily injections to
control glucose levels. It is widely believed that longer
acting insulin formulations can lead to improved patient
compliance with therapeutic regimes and ultimately better
health overall.
One injection of EDP’s lead drug candidate, SIA-II insulin has
demonstrated tight glucose control for 140+ days in
established diabetic animal models. Secondary complications
usually associated with diabetes were also significantly
reduced in SIA-II treated animals. This data has recently been
published in Proceedings of the National Academy of Sciences
of the USA.
EDP is developing SIA-II in the USA and internationally. Our
hope is to ultimately improve the prognosis of diabetes
patients world-wide.
